Tuesday 17 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterpriseVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Deals & M&A

ENDRA reports Q3 net loss of $1.5m as Noble Africa merger awaits closing conditions

The liver-fat imaging developer says merger-related fees lifted G&A costs while R&D spending fell, with the proposed deal with an ASP Isotopes subsidiary still pending approvals.

16 Nov 2026 · ENDRA Life Sciences Inc. NDRA · Company news

ENDRA Life Sciences reported a net loss of $1.5 million for the third quarter of 2026 on 16 November, narrowing from $1.6 million in the same period a year earlier.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): ENDRA Life Sciences Inc. ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More Deals & M&AAll →